Literature DB >> 26163327

Protective effects of simvastatin administered in the experimental hepatic ischemia-reperfusion injury rat model.

Fatma Emel Kocak1, Aysegul Kucuk2, Filiz Ozyigit3, Murat Tosun4, Cengiz Kocak5, Ahmet Kocak6, Mehmet Fatih Ekici7, Faik Yaylak8, Osman Genc2.   

Abstract

BACKGROUND: Hepatic ischemia-reperfusion (I/R) injury is a major complication in clinical practice. Previous studies suggest that statins have pleiotropic effects in addition to cholesterol-lowering effects. In this study, we aimed to investigate the hepatoprotective role of two different doses of simvastatin (SV) pretreatment in rats with experimental hepatic I/R injury.
METHODS: Adult male Sprague-Dawley rats were divided into four groups (n = 7 in each group) :control, I/R, I/R with 2.5-mg/kg SV, and I/R with 5.0-mg/kg SV. Before hepatic I/R was induced, SV was injected intraperitoneally at doses of 2.5 and 5.0 mg/kg. After 45-min ischemia and a 60-min reperfusion period, the animals were euthanized, and liver tissues were excised. Tissue levels of malondialdehyde and nitric oxide, and activities of superoxide dismutase, glutathione peroxidase, and catalase were measured. Liver tissues were also evaluated histopathologically and immunohistochemically.
RESULTS: Histopathologic evaluation showed that 5.0-mg/kg SV reduced hepatic damage and apoptosis. Pretreatment with 5.0-mg/kg SV reduced malondialdehyde and nitric oxide levels (P < 0.01) and increased superoxide dismutase, glutathione peroxidase, and catalase activities significantly (P < 0.001, P < 0.01) in I/R with 2.5-mg/kg SV compared with I/R group. In addition, SV decreased Kupffer cell activation, and hypoxia-inducible factor-1α and vascular endothelial growth factor protein levels.
CONCLUSIONS: The results of this study suggest that 5.0-mg/kg SV pretreatment may be protective against hepatic I/R injury. This effect can be achieved by antioxidant and antiapoptotic activities.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hepatic ischemia–reperfusion injury; Liver; Simvastatin

Mesh:

Substances:

Year:  2015        PMID: 26163327     DOI: 10.1016/j.jss.2015.06.009

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  4 in total

1.  Atorvastatin does not protect against ischemia-reperfusion damage in cholestatic rat livers.

Authors:  Jimme K Wiggers; Rowan F van Golen; Joanne Verheij; Annemiek M Dekker; Thomas M van Gulik; Michal Heger
Journal:  BMC Surg       Date:  2017-04-11       Impact factor: 2.102

2.  Effect of Ischemic Postconditioning and Atorvastatin in the Prevention of Remote Lung Reperfusion Injury.

Authors:  Carlos Henrique Marques Dos Santos; Doroty Mesquita Dourado; Baldomero Antonio Kato da Silva; Henrique Budib Dorsa Pontes; Euler de Azevedo Neto; Giovanna Serra da Cruz Vendas; Ian de Oliveira Chaves; João Victor Cunha Miranda; João Victor Durães Gomes Oliva; Letícia do Espírito Santo Dias; Murillo Henrique Martins de Almeida; Trícia Luna Sampaio
Journal:  Braz J Cardiovasc Surg       Date:  2018 Mar-Apr

3.  ATORVASTATIN CAN PREVENT HEPATIC REMOTE REPERFUSION INJURY.

Authors:  Carlos Henrique Marques Dos Santos; Doroty Mesquita Dourado; Baldomero Antonio Kato da Silva; Henrique Budib Dorsa Pontes; Euler de Azevedo-Neto; Giovanna Serra da Cruz Vendas; Ian de Oliveira Chaves; João Victor Cunha Miranda
Journal:  Arq Bras Cir Dig       Date:  2017 Jul-Sep

4.  Atorvastatin mitigates cyclophosphamide-induced hepatotoxicity via suppression of oxidative stress and apoptosis in rat model.

Authors:  Maedeh Hamzeh; Seyed Jalal Hosseinimehr; Ali Reza Khalatbary; Hamid Reza Mohammadi; Ayat Dashti; Fereshteh Talebpour Amiri
Journal:  Res Pharm Sci       Date:  2018-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.